Rufinamide

Drug Profile

Rufinamide

Alternative Names: Banzel; CGP 33101; E 2080; Inovelon; RUF 331; SYN 111; Xilep™

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Biotie Therapies Corp.; Eisai Co Ltd
  • Class Antiepileptic drugs; Small molecules; Triazoles
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Lennox-Gastaut syndrome
  • No development reported Epilepsy
  • Discontinued Generalised anxiety disorder; Neuropathic pain

Most Recent Events

  • 05 Dec 2016 Adverse events data from the pooled analysis in Lennox-Gastaut syndrome released by Esai
  • 05 Dec 2016 Final efficacy data from a phase III trial in Lennox-Gastaut syndrome released by Eisai
  • 19 May 2016 Launched for Lennox-Gastaut syndrome (Adjunctive treatment) in Israel (PO) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top